ScreenerHero

ALT Altimmune, Inc.

NAS · US · Healthcare · Biotechnology · altimmune.com
2.660USD-0.37%Mkt Cap: 517.42M $P/E: —

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap517.42M USD
Enterprise Value229.10M USD
Revenue (TTM)31.00K USD
Gross Profit-66.69M USD
Net Income (TTM)-88.09M USD
Revenue/Share0.00 USD
Last Price2.660 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees57
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.00
PEG32.62
EV/EBITDA-2.32
EV/Revenue7390.36
P/S16753.62
P/B1.10
EPS (TTM)-0.76
EPS (Forward)-0.67
52W Range
2.5603% of range6.440
52W High6.440 USD
52W Low2.560 USD
Profitability
Gross Margin0.00%
Oper. Margin-318493.55%
EBITDA Margin0.00%
Profit Margin-214860.98%
ROE-39.17%
ROA-31.47%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-67.53M USD
CapEx (TTM)11.00K USD
FCF Margin-157374.59%
FCF Yield-9.43%
Net Debt-290.26M USD
Net Debt/EBITDA2.94
Balance Sheet
Debt/Equity0.16
Current Ratio26.78
Quick Ratio26.37
Book Value/Sh2.44 USD
Cash/Share1.68 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJan 20, 2017
Pay DateSep 14, 2018
Splits
Last Split1:30
Split DateSep 14, 2018
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.11 USD
Upside (mean)+543.3%
Target Range11.00 USD – 28.00 USD
11.00+543.3% to mean28.00
# Analysts9
Ownership
Shares Out.194.52M
Float164.38M
Insiders0.42%
Institutions77.86%
Short Interest
Short Ratio13.5d
Short % Float26.64%
Short % Out.26.60%
Shares Short51.75M
Short (prev mo.)50.97M
Technical
SMA 503.084 (-13.8%)
SMA 2003.448 (-22.9%)
Beta0.06
S&P 52W Chg16.45%
Avg Vol (30d)4.15M
Avg Vol (10d)3.76M
Technical Indicators
RSI (14)29.9
MACD-0.1194
MACD Signal-0.0558
MACD Hist.-0.0636
BB Upper3.587 USD
BB Middle3.065 USD
BB Lower2.543 USD
BB Width34.07%
ATR (14)0.1293 USD
Vol Ratio (20d)0.81x